» Articles » PMID: 33554041

Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials

Overview
Specialty Oncology
Date 2021 Feb 8
PMID 33554041
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Higher mammographic breast density (MBD) is associated with an increased risk of breast cancer when compared with lower MBD, especially in premenopausal women. However, little is known about the effectiveness of chemoprevention agents in reducing MBD in premenopausal women without a history of breast cancer. Findings from this review should provide insight on how to target MBD in breast cancer prevention in premenopausal women with dense breasts.

Methods: We searched 9 electronic databases for clinical trials in English, Spanish, French, or German published until January 2020. Articles evaluating the association of pharmacological agents and MBD were included. Data were extracted on methods, type and dose of intervention, outcomes, side effects, and follow up. Quality of the studies was assessed using the US Preventive Services Task Force criteria.

Results: We identified 7 clinical trials evaluating the associations of 6 chemoprevention agents with changes in MBD in premenopausal women without history of breast cancer. The studies evaluated selective estrogen-receptor modulators (n = 1); gonadotropin-releasing hormone agonists (n = 2); isoflavones (n = 1); vitamin D (n = 1); and Boswellia, betaine, and mayo-inositol compound (n = 1). Hormonal interventions were associated with net reductions in percent density (tamoxifen [13.4%], leuprolide acetate [8.9%], and goserelin [2.7%]), whereas nonhormonal (vitamin D and isoflavone) interventions were not. However, MBD returned to preintervention baseline levels after cessation of gonadotropin-releasing hormone agonists.

Conclusions: A limited number of chemoprevention agents have been shown to reduce MBD in premenopausal women. Identification of new and well-tolerated chemoprevention agents targeting MBD and larger studies to confirm agents that have been studied in small trials are urgent priorities for primary breast cancer prevention in premenopausal women with dense breasts.

Citing Articles

Repeated measures of mammographic density and texture to evaluate prediction and risk of breast cancer: a systematic review of the methods used in the literature.

Anandarajah A, Chen Y, Stoll C, Hardi A, Jiang S, Colditz G Cancer Causes Control. 2023; 34(11):939-948.

PMID: 37340148 PMC: 10533570. DOI: 10.1007/s10552-023-01739-2.


In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases.

Tasdemiroglu Y, Gourdie R, He J Eur J Pharmacol. 2022; 932:175192.

PMID: 35981605 PMC: 9687107. DOI: 10.1016/j.ejphar.2022.175192.


Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.

Mohammed G, Mousa N, Talaat I, Ibrahim H, Saber-Ayad M Front Endocrinol (Lausanne). 2022; 12:781066.

PMID: 34975755 PMC: 8719328. DOI: 10.3389/fendo.2021.781066.


RE: Chemopreventive Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.

Hopper J, Nguyen T, Li S JNCI Cancer Spectr. 2021; 5(4).

PMID: 34377932 PMC: 8346692. DOI: 10.1093/jncics/pkab051.

References
1.
Assi V, Massat N, Thomas S, Mackay J, Warwick J, Kataoka M . A case-control study to assess the impact of mammographic density on breast cancer risk in women aged 40-49 at intermediate familial risk. Int J Cancer. 2014; 136(10):2378-87. DOI: 10.1002/ijc.29275. View

2.
Boyd N, Martin L, Chavez S, Gunasekara A, Salleh A, Melnichouk O . Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study. Lancet Oncol. 2009; 10(6):569-80. DOI: 10.1016/S1470-2045(09)70078-6. View

3.
Heller S, Hudson S, Wilkinson L . Breast density across a regional screening population: effects of age, ethnicity and deprivation. Br J Radiol. 2015; 88(1055):20150242. PMC: 4743450. DOI: 10.1259/bjr.20150242. View

4.
Chen M, Rao Y, Zheng Y, Wei S, Li Y, Guo T . Association between soy isoflavone intake and breast cancer risk for pre- and post-menopausal women: a meta-analysis of epidemiological studies. PLoS One. 2014; 9(2):e89288. PMC: 3930722. DOI: 10.1371/journal.pone.0089288. View

5.
Engmann N, Golmakani M, Miglioretti D, Sprague B, Kerlikowske K . Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer. JAMA Oncol. 2017; 3(9):1228-1236. PMC: 5540816. DOI: 10.1001/jamaoncol.2016.6326. View